Obermeyer Wood Investment Counsel Lllp decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 11,097 shares of the company’s stock after selling 300 shares during the period. Obermeyer Wood Investment Counsel Lllp’s holdings in IDEXX Laboratories were worth $1,735,000 as of its most recent filing with the SEC.
A number of other large investors have also modified their holdings of the business. Zions Bancorporation bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $162,000. Benjamin F. Edwards & Company Inc. grew its stake in shares of IDEXX Laboratories by 1,000.0% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock valued at $172,000 after purchasing an additional 1,000 shares during the period. SignalPoint Asset Management LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at about $200,000. Ledyard National Bank grew its stake in shares of IDEXX Laboratories by 58.9% during the 4th quarter. Ledyard National Bank now owns 1,295 shares of the company’s stock valued at $203,000 after purchasing an additional 480 shares during the period. Finally, BB&T Securities LLC bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $213,000. 86.02% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have issued reports on the company. Aegis restated a “sell” rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. Canaccord Genuity restated a “buy” rating and set a $210.00 price target on shares of IDEXX Laboratories in a research note on Monday, January 29th. Piper Jaffray Companies assumed coverage on IDEXX Laboratories in a research note on Tuesday, January 16th. They set an “overweight” rating and a $200.00 price target for the company. Bank of America boosted their price target on IDEXX Laboratories from $200.00 to $220.00 and gave the company a “buy” rating in a research note on Friday, February 2nd. Finally, BidaskClub upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating to the company. IDEXX Laboratories currently has an average rating of “Buy” and an average price target of $194.00.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.77 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.04. The company had revenue of $506.00 million during the quarter, compared to the consensus estimate of $490.51 million. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The firm’s revenue was up 14.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.58 EPS. equities research analysts anticipate that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current year.
In related news, Director William T. End sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $184.48, for a total transaction of $737,920.00. Following the completion of the transaction, the director now directly owns 41,256 shares in the company, valued at approximately $7,610,906.88. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Jonathan W. Ayers sold 2,160 shares of the business’s stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $167.03, for a total value of $360,784.80. Following the transaction, the chief executive officer now owns 1,077,112 shares of the company’s stock, valued at $179,910,017.36. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 90,762 shares of company stock valued at $15,940,404. 2.77% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “IDEXX Laboratories, Inc. (IDXX) Holdings Trimmed by Obermeyer Wood Investment Counsel Lllp” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3225940/idexx-laboratories-inc-idxx-holdings-trimmed-by-obermeyer-wood-investment-counsel-lllp.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.